OrbiMed Advisors ABCL Position
Exited4-Fund ConvergenceOrbiMed Advisors exited their position in AbCellera Biologics Inc. (ABCL) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
ABCL is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ABCL635 in 318 days (Feb 28, 2027), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 21.5% of float with 14.3 days to cover, indicating significant bearish positioning against the stock.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Full company profile →Short Interest
21.5%
14.3 days to cover
OrbiMed Advisors ABCL Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -3,344,568 | $0 |
| Q2 2025 | Decreased | 3,344,568 | -836,200 | $11.5M |
| Q1 2025 | Held | 4,180,768 | — | $9.3M |
| Q4 2024 | Held | 4,180,768 | — | $12.3M |
| Q3 2024 | Held | 4,180,768 | — | $10.9M |
| Q2 2024 | Held | 4,180,768 | — | $12.4M |
| Q1 2024 | Held | 4,180,768 | — | $18.9M |
| Q4 2023 | Held | 4,180,768 | — | $23.9M |
| Q3 2023 | Held | 4,180,768 | — | $19.2M |
| Q2 2023 | Held | 4,180,768 | — | $27.0M |
| Q1 2023 | New | 4,180,768 | +4,180,768 | $31.5M |
Frequently Asked Questions
Does OrbiMed Advisors own ABCL?
No. OrbiMed Advisors exited their position in AbCellera Biologics Inc. (ABCL) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own ABCL?
4 specialist biotech hedge funds currently hold ABCL, including Baker Bros. Advisors, Casdin Capital, Tang Capital Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy ABCL?
OrbiMed Advisors's position in ABCL was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's ABCL position increasing or decreasing?
OrbiMed Advisors completely exited their ABCL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ABCLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →